ReachRxResearch
Home
Research
Sign Up
Treatment Choice and Cardiovascular Risk in Chronic Spontaneous Urticaria
Back to Research Hub
  1. Home
  2. Research Hub
  3. Treatment Choice and Cardiovascular Risk…

Treatment Choice and Cardiovascular Risk in Chronic Spontaneous Urticaria

Clinical and Translational Allergy·October 21Open Access
AllergyPractice changingCardiovascular DiseaseChronic Spontaneous UrticariaRetrospective Matched Cohort StudyAntihistamineBiologic (Anti-IgE)Oral CorticosteroidAdultXolairOmalizumab

Summary

View source

What was studied

This retrospective matched cohort study used the TriNetX US Collaborative Network to compare cardiovascular disease (CVD) risk in adult CSU patients treated with omalizumab (OMA), second-generation antihistamines (sgAH), or oral corticosteroids (oCS), across three pairwise 1:1 propensity-score-matched analyses over up to 3 years.

Key findings

OMA was consistently associated with the lowest CVD risk: vs. oCS, absolute risk was 3.55% vs. 8.06% (primary analysis), with adjusted hazard ratios of 0.51–0.54 (all p<0.001); sgAH showed modestly lower CVD risk than oCS; the hierarchy OMA < sgAH < oCS was directionally consistent across all predefined time windows and secondary outcomes (MACE, VTE).

Study limitations

Treatment allocation was non-random and may capture disease severity rather than drug effects; omalizumab patients may have had more stable disease, more intensive surveillance, and higher socioeconomic status; disease control was not measured, so whether lower CVD risk reflects drug-specific effects, better CSU control, or residual confounding cannot be determined.

Clinical implications

Clinicians managing CSU should be aware that CVD risk varies by treatment choice, with omalizumab associated with the lowest observed risk — but these findings should prompt CVD risk assessment in CSU management rather than be interpreted as proof that omalizumab is cardioprotective.

Caveats

  • Cohort sizes are highly unequal (~3,300 OMA vs. ~31,000 sgAH/oCS), which may affect precision and comparability of estimates
  • Funding came partly from Novartis (omalizumab manufacturer), and one author received Novartis funding to support this study — findings favoring omalizumab should be interpreted with this conflict in mind
  • Reciprocal exclusion of oCS after index may have selected a more stable, less severe omalizumab-treated population, inflating the apparent cardiovascular benefit of omalizumab
Show all 4
  • The study relies on administrative diagnosis codes from a US network database (TriNetX); disease severity, disease control, and socioeconomic status were only partially captured, limiting causal inference

Related Questions

Explore related topics

Does omalizumab reduce cardiovascular risk in chronic spontaneous urticaria?Cardiovascular outcomes in chronic spontaneous urticaria compared to general populationOral corticosteroids and cardiovascular risk in inflammatory skin diseases

Publication Details

Year
2026
Journal
Clinical and Translational Allergy
Sample Size
n=68,600
Source
View article
Keep scrolling
More content below.
Up Next